Receptor-coupled, DAG-gated Ca2+-permeable cationic channels in LNCaP human prostate cancer epithelial cells.
Although the prostate gland is a rich source of alpha1-adreno- (alpha1-AR) and m1-cholino receptors (m1-AChR), the membrane processes associated with their activation in glandular epithelial cells is poorly understood. We used the whole-cell patch-clamp technique to show that the agonists of the respective receptors, phenylephrine (PHE) and carbachol (CCh), activate cationic membrane currents in lymph node carcinoma of the prostate (LNCaP) human prostate cancer epithelial cells, which are not dependent on the filling status of intracellular IP3-sensitive Ca2+ stores, but directly gated by diacylglycerol (DAG), as evidenced by the ability of its membrane permeable analogue, OAG, to mimic the effects of the agonists. The underlying cationic channels are characterized by the weak field-strength Eisenman IV permeability sequence for monovalent cations (PK(25) > PCs(4.6) > PLi(1.4) > PNa(1.0)), and the following permeability sequence for divalent cations: PCa(1.0) > PMg(0.74) > PBa(0.6) > PSr(0.36) > PMn(0.3). They are 4.3 times more permeable to Ca2+ than Na+ and more sensitive to the inhibitor 2-APB than SK&F 96365. RT-PCR analysis shows that DAG-gated members of the transient receptor potential (TRP) channel family, including TRPC1 and TRPC3, are present in LNCaP cells. We conclude that, in prostate cancer epithelial cells, alpha1-ARs and m1-AChRs are functionally coupled to Ca2+-permeable DAG-gated cationic channels, for which TRPC1 and TRPC3 are the most likely candidates.
Sydorenko
V
V
Laboratoire de Physiologie Cellulaire, INSERM EMI 0228, Bâtiment SN3, USTL, 59655 Villeneuve d'Ascq, France.
Shuba
Y
Y
Thebault
S
S
Roudbaraki
M
M
Lepage
G
G
Prevarskaya
N
N
Skryma
R
R
D001483:Base Sequence; D015220:Calcium Channels / Q000502:physiology; D002217:Carbachol / Q000494:pharmacology*; D017931:DNA Primers; D004594:Electrophysiology / Q000379:methods; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007473:Ion Channels / Q000235:genetics / Q000502:physiology*; D008297:Male; D010656:Phenylephrine / Q000494:pharmacology*; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology; D011471:Prostatic Neoplasms; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects / Q000502:physiology; D011976:Receptors, Muscarinic / Q000502:physiology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012430:Ruthenium Red / Q000494:pharmacology; D050052:TRPC Cation Channels; D019789:Tetraethylammonium / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D015220:Calcium Channels; D017931:DNA Primers; D007473:Ion Channels; D015221:Potassium Channels; D018340:Receptors, Adrenergic, alpha-1; D011976:Receptors, Muscarinic; D050052:TRPC Cation Channels; C096351:transient receptor potential cation channel, subfamily C, member 1; D012430:Ruthenium Red; D010656:Phenylephrine; D019789:Tetraethylammonium; D002217:Carbachol